0B68 Dicker, Adam P. - Thomas Jefferson University - Thomas Jefferson University

Adam P. Dicker, MD, PhD

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  2. AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: Report of Task Group 192
  3. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  4. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  5. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
  6. High dose rate brachytherapy boost for prostate cancer: A systematic review
  7. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
  8. A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
  9. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  10. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  11. The quality frontier
  12. High-priority topics for cancer quality measure development: Results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit
  13. Study of unrecovered strain and critical stresses in one-way shape memory Nitinol
  14. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma
  15. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  16. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
  17. MicroRNAs: The short link between cancer and RT-induced DNA damage response
  18. A model to predict deflection of bevel-tipped active needle advancing in soft tissue
  19. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
  20. Polyacrylamide phantom for self-actuating needle-tissue interaction studies